Neurocrine Biosciences, Inc.

Neurocrine Biosciences’ NBI-1117568 has shown significant improvement in symptoms and overall severity in adults with schizophrenia in new data presented from a Phase II dose-finding study, and the co

Executives still were struggling to understand the potential impact of President Trump’s executive order on US drug pricing for their companies’ top and bottom lines the day after its announcement. Tr

Industry leaders attending the Bank of America Global Healthcare Conference 13-14 May were pressed for early reaction to President Donald Trump’s executive order on US drug pricing, but with the confe

Neurocrine Updates On Crenessity Launch Neurocrine Biosciences announced encouraging early sales for its new commercial product, Crenessity (crinecerfont), in its first full quarter of launch. Crene